KN057 not checked

Suzhou Alphamab Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor, Hemophilia A or B, Hemophilia a and B
Main trialPhase 3
“The purpose of this study is to show that KN057 can prevent bleeds in patients with haemophilia A or B with inhibitors and is safe to use. Successfully screened participants will be randomly assigned to KN057 Prophylaxis (Arm 1) versus No Prophylaxis (Arm 2) at a ratio of 2:1. Participants in KN057 Prophylaxis will receive KN057 prophylaxis for 52 weeks upon enrollment. Participants in No Prophylaxis will first receive on-demand treatment for 26 weeks, then switch to KN057 prophylaxis for 26 weeks.The trial period is 59 weeks, including a 3-week screening period, a 26-week main trial, a…”In the company’s words, NCT06312475 on ClinicalTrials.gov

Other drugs for Hemophilia A With Inhibitor

All 26 drugs for Hemophilia A With Inhibitor

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 15 Oct 2025 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
Phase 3Active, not recruiting 15 Oct 2026 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
Phase 3Recruiting 30 Dec 2027 Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Phase 2Not yet recruiting 2 Sep 2026 KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
Phase 2Completed 17 Jan 2024 KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow KN057

Following is part of Solo: you see every change to KN057 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in